Session Details

F026 Granulomatous Disorders of the Adult Skin

Sat, Mar 20, 1:00 PM - 3:00 PM
2 CME Available Forum

DESCRIPTION

Come to the best session at the Academy! Learn about all the things you hope you don't have to see/diagnose/manage (or if you love them, come hang out with your fellows!)
Granulomatous disorders represent a unique group of diseases, both noninfectious and infectious, that require clinical pathological correlation combined with an understanding of underlying systemic disease and appropriate pharmacologic interventions. Dermatologists need to be able to differentiate granuloma annulare, sarcoidosis, necrobiosis lipoidica, reactive granulomatous dermatitis and drug-induced granulomatous reactions, NXG, Rubella-granulomas, and more! Learn how to evaluate patients for underlying systemic diseases, and treat them with appropriate therapeutic agents.

LEARNING OBJECTIVES

1.

Review granulomatous diseases of the skin, providing a framework to recognize different clinical presentations, interpret dermatopathology, evaluate patients for systemic disease involvement, and develop an approach to treatment

2.

Identify characteristics of and differentiate between Granuloma Annulare, Necrobiosis Lipoidica, Sarcoidosis, Reactive Granulomatous Diseases (IGD/PNGD), Necrobiotic Xanthogranuloma, Cutaneous Crohn Disease, and more

3.

Discuss translational advances, personalized medicine, novel therapeutics, and targeted approaches to treatments

SCHEDULE

1:00 PM

Introduction

Misha Rosenbach, MD, FAAD

1:05 PM

Granuloma Annulare

Bridget Shields, MD, FAAD

1:15 PM

Necrobiosis Lipoidica

Claire Hannah, MD, FAAD

1:25 PM

Sarcoidosis

Sotonye Imadojemu, MD, FAAD

1:35 PM

Necrobiotic Xanthogranuloma

Sung Kyung Cho, MD

1:45 PM

Cutaneous Crohns, Granulomatous Cheilitis, OFG

Alexandra Coromilas, MD, FAAD

1:55 PM

JAKi's and Emerging Therapeutics

William Damsky, PhD, MD, FAAD

2:05 PM

Reactive Granulomatous Dermatitis

Avrom Caplan, MD, FAAD

2:15 PM

Rubella virus associated Granulomatous Dermatitis

Karolyn Wanat, MD, FAAD

2:25 PM

Granulomatous Mastitis

Mariam Laura Alam, MD, FAAD

2:35 PM

Granulomatous Drug Reactions

Emily R. Nadelmann, MD, FAAD

DIRECTOR

Misha Rosenbach, MD, FAAD

Misha Rosenbach, MD, FAAD

University of Pennsylvania

SPEAKERS

Mariam Laura Alam, MD, FAAD

Mariam Laura Alam, MD, FAAD

Avrom Caplan, MD, FAAD

Avrom Caplan, MD, FAAD

Sung Kyung Cho, MD

Sung Kyung Cho, MD

Alexandra Coromilas, MD, FAAD

Alexandra Coromilas, MD, FAAD

William Damsky, PhD, MD, FAAD

William Damsky, PhD, MD, FAAD

Claire Hannah, MD, FAAD

Claire Hannah, MD, FAAD

Sotonye Imadojemu, MD, FAAD

Sotonye Imadojemu, MD, FAAD

Emily R. Nadelmann, MD, FAAD

Emily R. Nadelmann, MD, FAAD

Bridget Shields, MD, FAAD

Bridget Shields, MD, FAAD

Karolyn Wanat, MD, FAAD

Karolyn Wanat, MD, FAAD

DISCLOSURES

Mariam Laura Alam, MD, FAAD

No financial relationships exist with ineligible companies.

Avrom Caplan, MD, FAAD

Novartis – Consultant (1099 relationship)(Fees); Priovant Therapeutics – Advisory Board(Fees), Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding);

Alexandra Coromilas, MD, FAAD

No financial relationships exist with ineligible companies.

William Damsky, PhD, MD, FAAD

AbbVie – Investigator(Fees); Advanced Cell Diagnostics, Inc. – Investigator(Equipment); Boehringer Ingelheim – Consultant (1099 relationship)(Fees); Bristol – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Investigator(Grants/Research Funding); CSL Behring – Consultant (1099 relationship)(Fees); Eli Lilly and Company – Consultant(Fees); Epiarx Diagnostics – Consultant (1099 relationship)(Fees); Fresenius Kabi – Consultant (1099 relationship)(Fees); Incite – Investigator(Grants/Research Funding); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); MilliporeSigma – Other(Patent royalties or other compensation for Intellectual Property Rights); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Priovant Therapeutics – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); TWi Biote – Consultant (1099 relationship)(Fees); TWi Biotechnology, Inc. – Consultant(Fees), Consultant (1099 relationship)(Fees), Investigator(Fees);

Claire Hannah, MD, FAAD

Priovant Therapeutics – Investigator(Grants/Research Funding);

Sotonye Imadojemu, MD, FAAD

No financial relationships exist with ineligible companies.

Emily R. Nadelmann, MD, FAAD

No financial relationships exist with ineligible companies.

Misha Rosenbach, MD, FAAD

Google Ventures – Consultant (1099 relationship)(Honoraria); J&J Innovative Medicine – Consultant(Honoraria); Merck & Co., Inc – Consultant(Honoraria); OpenEvidence – Advisory Board(Other Financial Benefit); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding);

Bridget Shields, MD, FAAD

Arcutis Biotherapeutics – Consultant (1099 relationship)(Honoraria); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria); UpToDate, Inc – Other(Honoraria);

Karolyn Wanat, MD, FAAD

No financial relationships exist with ineligible companies.